{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16721205",
  "DateCompleted": {
    "Year": "2006",
    "Month": "10",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "11",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1558-2027",
      "JournalIssue": {
        "Volume": "7",
        "Issue": "6",
        "PubDate": {
          "Year": "2006",
          "Month": "Jun"
        }
      },
      "Title": "Journal of cardiovascular medicine (Hagerstown, Md.)",
      "ISOAbbreviation": "J Cardiovasc Med (Hagerstown)"
    },
    "ArticleTitle": "Secondary prevention of myocardial infarction: a survey in primary care.",
    "Pagination": {
      "StartPage": "422",
      "EndPage": "426",
      "MedlinePgn": "422-6"
    },
    "Abstract": {
      "AbstractText": [
        "To collect information on the major risk factors and secondary prevention among patients with myocardial infarction in Italy.",
        "Data were obtained from the database of the Italian College of General Practitioners; 3588 patients (mean age 68.7 +/- 11.3 years; 2698 men, 888 women; two unrecorded gender), with an average time from event of 6 +/- 5.7 years, were identified.",
        "Among the major risk factors, data entry ranged from 50.3% for physical activity to 74.9% for blood pressure. Inadequate blood pressure control was present in 49.2% and elevated plasma cholesterol levels (> 5.2 mmol/l) in 57.3%; among the latter group, 65% were on lipid-lowering therapy. Only 47.2% of the treated patients achieved a total cholesterol level of < 5.2 mmol/l. Antiplatelet or anticoagulant drugs, beta-blockers, and angiotensin-converting enzyme inhibitors were prescribed to 43%, 10.3%, and 57.9% of patients, respectively.",
        "The preventive attitude of Italian general practitioners is similar to that reported in other European countries with two noticeable exceptions: under-prescription of beta-blockers and of antiplatelet drugs. Clearly, secondary prevention requires major improvement."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Italian College of General Practitioners, Florence, Italy."
          }
        ],
        "LastName": "Filippi",
        "ForeName": "Alessandro",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Vanuzzo",
        "ForeName": "Diego",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bignamini",
        "ForeName": "Angelo A",
        "Initials": "AA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mazzaglia",
        "ForeName": "Gianpiero",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Brignoli",
        "ForeName": "Ovidio",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sabatini",
        "ForeName": "Andrea",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cricelli",
        "ForeName": "Claudio",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Catapano",
        "ForeName": "Alberico L",
        "Initials": "AL"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Cardiovasc Med (Hagerstown)",
    "NlmUniqueID": "101259752",
    "ISSNLinking": "1558-2027"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anticoagulants"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Lipids"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Platelet Aggregation Inhibitors"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Anticoagulants"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Italy"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Lipids"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Myocardial Infarction"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Platelet Aggregation Inhibitors"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Practice Patterns, Physicians'"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Primary Health Care"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    }
  ]
}